These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15111335)

  • 1. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.
    Rizzoli R
    Ann Oncol; 2004 May; 15(5):700-1. PubMed ID: 15111335
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.
    Westermann AM
    Ann Oncol; 2004 Mar; 15(3):537-8. PubMed ID: 14998861
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.
    Body JJ; Diel IJ; Lichinitzer M; Lazarev A; Pecherstorfer M; Bell R; Tripathy D; Bergstrom B
    Br J Cancer; 2004 Mar; 90(6):1133-7. PubMed ID: 15026791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibandronate in metastatic bone pain.
    Heidenreich A; Ohlmann C; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
    McCormack PL; Plosker GL
    Drugs; 2006; 66(5):711-28. PubMed ID: 16620148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibandronate reduces skeletal morbidity in patients with breast cancer.
    Tripathy A D; Diel I; Body JJ
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):64-6. PubMed ID: 15490378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in breast cancer.
    Coleman RE
    Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.
    Tripathy D; Lichinitzer M; Lazarev A; MacLachlan SA; Apffelstaedt J; Budde M; Bergstrom B;
    Ann Oncol; 2004 May; 15(5):743-50. PubMed ID: 15111341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
    Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
    Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing metastatic bone disease: three case studies.
    Coleman R; Heidenreich A; Bell R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):83-6. PubMed ID: 15490382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
    Mystakidou K; Stathopoulou E; Parpa E; Kouloulias V; Kouskouni E; Vlahos L
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1303-10. PubMed ID: 18504612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates for breast cancer.
    Pavlakis N; Stockler M
    Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RIB trial.
    Hoskin PJ
    Clin Oncol (R Coll Radiol); 2004 Oct; 16(7):445-6. PubMed ID: 15490803
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bone metastases in breast carcinoma. Bisphosphonate protects from complications].
    MMW Fortschr Med; 2004 Apr; 146(14):45. PubMed ID: 15344758
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
    Harvey HA
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bisphosphonates in radiotherapy].
    Radiologe; 1997 Jan; 37(1 Suppl):1-4. PubMed ID: 9131097
    [No Abstract]   [Full Text] [Related]  

  • 19. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.